DEA Selects Only Rescheduling Opponents for Landmark Marijuana Hearing

The U.S. Drug Enforcement Administration will open a critical administrative hearing on June 29 to weigh the proposed move of marijuana from Schedule I to Schedule III of the Controlled Substances Act. An administrative law judge will preside over the expedited proceedings, which are tasked with comprehensively examining the merits of rescheduling the federally prohibited substance.

The hearing stems from a broader push to align federal policy with scientific evaluations and state-level reforms. It follows an earlier Justice Department action in April that placed FDA-approved marijuana-derived products and state-licensed medical cannabis into Schedule III. The upcoming sessions will address whether that change should extend to marijuana more broadly.

In a move drawing immediate scrutiny, the DEA has invited only parties opposed to the reform to participate as interested persons. The selected participants are:

• DUID Victim Voices
• Tennessee Bureau of Investigation
• Smart Approaches to Marijuana
• National Drug & Alcohol Screening Association
• The states of Nebraska, Idaho, Indiana, and Louisiana
• Kenneth Finn, MD
• Phillip A. Drum, PharmD

These organizations, states, and experts have consistently voiced concerns about marijuana’s potential for abuse, public health risks, impaired driving, and youth access. Many have actively opposed rescheduling efforts in public comments and legal challenges.

The hearing is set to take place at the DEA Hearing Facility in Arlington and must conclude no later than July 15. Under the formal process, the administrative law judge will oversee testimony, evidence presentation, and cross-examination. The judge’s findings will help shape the final agency decision, though the DEA Administrator holds ultimate authority over the rulemaking.

Proponents of rescheduling have expressed disappointment over the participant slate. Groups advocating for reform, including those representing patients, researchers, and industry stakeholders, were largely excluded from formal participation. Critics argue the one-sided lineup may limit the hearing’s ability to fully reflect the extensive public record, which included tens of thousands of comments supporting the change based on accepted medical uses and reduced abuse potential compared to Schedule I drugs.

At stake is more than classification semantics. Moving marijuana to Schedule III could ease certain research restrictions, alter tax treatment for cannabis businesses, and signal greater federal recognition of its therapeutic value. Opponents, however, warn that rescheduling could normalize use, complicate drug testing protocols, and undermine state-level restrictions.

The proceedings unfold against a backdrop of evolving cannabis policy. Dozens of states have established medical or adult-use programs, creating a patchwork that clashes with federal prohibition. The hearing represents a key procedural step in addressing that disconnect.

As the June 29 start date approaches, all eyes will be on the administrative law judge’s management of the case and the testimony that emerges. The outcome is expected to influence not only federal enforcement priorities but also the trajectory of cannabis research, investment, and patient access nationwide.